Alexander Dömling Selected Research

Alexander Dömling Research Topics

Disease

29	Neoplasms (Cancer) 05/2022 - 01/2005
3	COVID-19 01/2022 - 12/2020
3	Inflammation (Inflammations) 01/2021 - 10/2017
3	Schistosomiasis (Bilharziasis) 04/2012 - 09/2010
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 04/2020
2	Asthma (Bronchial Asthma) 01/2021 - 10/2015
1	Animal Disease Models 01/2022
1	Neoplasm Metastasis (Metastasis) 03/2021
1	Carcinogenesis 01/2021
1	Infections 12/2020
1	Pathologic Processes 07/2020
1	Disease Progression 07/2020
1	Neurodegenerative Diseases (Neurodegenerative Disease) 07/2020
1	Atherosclerotic Plaque (Atheroma) 04/2020
1	Osteosarcoma (Osteogenic Sarcoma) 01/2019
1	Hypertension (High Blood Pressure) 11/2018
1	Melanoma (Melanoma, Malignant) 12/2015
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2015
1	Human Influenza (Influenza) 11/2015
1	Chronic Obstructive Pulmonary Disease (COPD) 10/2015
1	Chronic Bronchitis 10/2015
1	Lung Diseases (Lung Disease) 10/2015
1	Leukemia 03/2014
1	Merkel Cell Carcinoma 05/2012
1	Neglected Diseases 04/2012

Drug/Important Bio-Agent (IBA)

7	Pharmaceutical PreparationsIBA 01/2022 - 11/2010
7	Proteins (Proteins, Gene)FDA Link 12/2021 - 01/2011
6	AntibodiesIBA 05/2022 - 02/2014
6	Monoclonal AntibodiesIBA 01/2018 - 12/2015
3	Biological ProductsIBA 01/2021 - 04/2013
3	Praziquantel (Biltricide)FDA Link 04/2012 - 09/2010
2	Peptides (Polypeptides)IBA 01/2022 - 01/2018
2	Fluorouracil (Carac)FDA LinkGeneric 12/2021 - 01/2021
2	Peptide Hydrolases (Proteases)FDA Link 01/2021 - 12/2020
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021 - 04/2020
2	ArginaseIBA 01/2021 - 07/2020
2	Oncogene Proteins (Oncogene Protein)IBA 01/2017 - 05/2012
1	Oxidoreductases (Dehydrogenase)IBA 01/2021
1	3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)IBA 01/2021
1	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 12/2020
1	Biomarkers (Surrogate Marker)IBA 07/2020
1	LipidsIBA 04/2020
1	CholesterolIBA 04/2020
1	Atorvastatin (Lipitor)FDA Link 04/2020
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 04/2019
1	indoleIBA 01/2019
1	SilverIBA 11/2018
1	Epoxide HydrolasesIBA 11/2018
1	EnzymesIBA 01/2018
1	glucarpidaseIBA 01/2018
1	EpitopesIBA 01/2018
1	Methotrexate (Mexate)FDA LinkGeneric 01/2018
1	ProdrugsIBA 01/2018
1	gamma-Glutamyl Hydrolase (Carboxypeptidase G2)IBA 01/2018
1	Immune Checkpoint ProteinsIBA 01/2017
1	Tumor Suppressor Protein p53IBA 01/2017
1	Amantadine (Aman)FDA LinkGeneric 11/2015
1	AminesIBA 11/2015
1	Lipoxygenase (Lipoxygenase-1)IBA 10/2015
1	Carboxylic AcidsIBA 03/2014
1	EstersIBA 03/2014
1	ethyl 3- (2- ((tert- butylamino)- 1- (N- (4- chlorobenzyl)formamido)- 2- oxoethyl)- 6- chloro- 1H- indole- 2- carboxylateIBA 03/2014
1	LigandsIBA 02/2014
1	sepantroniumIBA 05/2012
1	SurvivinIBA 05/2012
1	Cytostatic AgentsIBA 05/2012
1	Bortezomib (Velcade)FDA Link 05/2012
1	1,2,3,4-tetrahydroisoquinolineIBA 04/2012
1	Cytotoxins (Cytolysins)IBA 01/2005
1	TubulinIBA 01/2005

Therapy/Procedure

10	Therapeutics 05/2021 - 01/2005
3	Immunotherapy 05/2019 - 02/2014
1	Drug Therapy (Chemotherapy) 01/2022
1	Secondary Prevention 04/2020